Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FCER2 | P06734 | 1/20 | 0.44 |
| ▸ | SYK | P43405 | 1/20 | 0.44 |
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.43 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.41 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | TLK2 | Q86UE8 | 1/20 | 0.39 |
| ▸ | PLAU | P00749 | 1/20 | 0.39 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.38 |
| ▸ | CCNC | P24863 | 1/20 | 0.38 |
| ▸ | CDK8 | P49336 | 1/20 | 0.38 |
| ▸ | OTUD7B | Q6GQQ9 | 1/20 | 0.38 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13712805 | 0.84 | SMYD3 (0.45) | SMYD3MAPK14PDK2 | |
| SCHEMBL10061664 | 0.82 | PDPK1 (0.55) | CRBNPDK2PDPK1 | |
| SCHEMBL10061663 | 0.81 | TLK2 (0.51) | FCER2SYKSMYD3TLK2PDPK1 | |
| SCHEMBL14446978 | 0.80 | PAK4 (0.58) | SMYD3 | |
| SCHEMBL13712799 | 0.79 | FCER2 (0.53) | FCER2SYKTLK2PDPK1 | |
| SCHEMBL11349200 | 0.76 | KMT2A (0.55) | PDK2HDAC8HDAC6HDAC2 | |
| SCHEMBL7233945 | 0.72 | TP53 (0.43) | FCER2SYKPDK2PDPK1 | |
| SCHEMBL7233951 | 0.72 | TP53 (0.43) | FCER2SYKPDK2PDPK1 | |
| SCHEMBL10061666 | 0.72 | ROS1 (0.61) | PDPK1 | |
| SCHEMBL31107477 | 0.72 | ROS1 (0.61) | PDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8207179-B2 | Substituted indolines as tyrosine kinase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-26 | — | — | US | disclosed |
| US-20100222331-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222331-A1 | NEW COMPOUNDS | CCNA1, CCNY, MKI67 | FCER2 4066/4885SYK 2888/4885SMYD3 2913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.